Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 3109135, 10 pages
http://dx.doi.org/10.1155/2016/3109135
Research Article

The Relationship of Cytokines IL-13 and IL-17 with Autoantibodies Profile in Early Rheumatoid Arthritis

1Department of Immunology, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania
2Department of Physiology, Titu Maiorescu University of Bucharest, 187 Calea Vacaresti Street, 004051 Bucharest, Romania
3Department of Medical Semiology, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania
4Department of Pharmacology, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania
5Medico Science SRL, Stem Cell Bank Unit, 1B Brazda lui Novac Street, 200690 Craiova, Romania
6Department of Microbiology, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania
7Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania
8Department of Surgery, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania

Received 19 February 2016; Revised 5 June 2016; Accepted 21 June 2016

Academic Editor: Oscar Bottasso

Copyright © 2016 Isabela Siloşi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Lutzky, S. Hannawi, and R. Thomas, “Cells of the synovium in rheumatoid arthritis. Dendritic cells,” Arthritis Research and Therapy, vol. 9, no. 4, article 219, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Choy, “Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis,” Rheumatology, vol. 51, supplement 5, Article ID kes113, pp. v3–v11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. J. S. Smolen and G. Steiner, “Therapeutic strategies for rheumatoid arthritis,” Nature Reviews Drug Discovery, vol. 2, no. 6, pp. 473–488, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. I. B. McInnes and G. Schett, “Cytokines in the pathogenesis of rheumatoid arthritis,” Nature Reviews Immunology, vol. 7, no. 6, pp. 429–442, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. S. Smolen, D. Aletaha, M. Koeller, M. H. Weisman, and P. Emery, “New therapies for treatment of rheumatoid arthritis,” The Lancet, vol. 370, no. 9602, pp. 1861–1874, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Aletaha, T. Neogi, A. J. Silman et al., “Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1580–1588, 2010. View at Publisher · View at Google Scholar
  7. C. A. Hitchon, P. Alex, L. B. Erdile et al., “A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis,” The Journal of Rheumatology, vol. 31, no. 12, pp. 2336–2346, 2004. View at Google Scholar · View at Scopus
  8. P. Emery and D. P. M. Symmons, “What is early rheumatoid arthritis?: definition and diagnosis,” Bailliere's Clinical Rheumatology, vol. 11, no. 1, pp. 13–26, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Gremese, F. Salaffi, S. L. Bosello et al., “Very early rheumatoid arthritis as a predictor of remission: A Multicentre Real Life Prospective Study,” Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 858–862, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. L. B. A. Van de Putte, A. M. Van Gestel, and P. L. C. M. Van Riel, “Early treatment of rheumatoid arthritis: rationale, evidence, and implications,” Annals of the Rheumatic Diseases, vol. 57, no. 9, pp. 511–512, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. T. R. Mikuls and J. O'Dell, “The changing face of rheumatoid arthritis therapy: results of serial surveys,” Arthritis and Rheumatism, vol. 43, no. 2, pp. 464–465, 2000. View at Google Scholar · View at Scopus
  12. M. A. S. Bukhari, N. J. Wiles, M. Lunt et al., “Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study,” Arthritis and Rheumatism, vol. 48, no. 1, pp. 46–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Kenis, C. Teunissen, R. De Jongh, E. Bosmans, H. Steinbusch, and M. Maes, “Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum,” Cytokine, vol. 19, no. 5, pp. 228–235, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Raza and D. M. Gerlag, “Preclinical inflammatory rheumatic diseases: an overview and relevant nomenclature,” Rheumatic Disease Clinics of North America, vol. 40, no. 4, pp. 569–580, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Önder, A. Kurtaran, S. Kimyon, B. Selçuk, and M. Akyüz, “Association of anti-CCP positivity with serum ferritin and DAS-28,” Rheumatology International, vol. 30, no. 2, pp. 223–227, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Zeidler, “The need to better classify and diagnose early and very early rheumatoid arthritis,” The Journal of Rheumatology, vol. 39, no. 2, pp. 212–217, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Roşu, C. Mărgăritescu, A. Stepan, A. Muşetescu, and M. Ene, “IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients,” Romanian Journal of Morphology and Embryology, vol. 53, no. 1, pp. 73–80, 2012. View at Google Scholar · View at Scopus
  19. P. Isomäki and J. Punnonen, “Pro- and anti-inflammatory cytokines in rheumatoid arthritis,” Annals of Medicine, vol. 29, no. 6, pp. 499–507, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Feldmann, F. M. Brennan, and R. N. Maini, “Role of cytokines in rheumatoid arthritis,” Annual Review of Immunology, vol. 14, pp. 397–440, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Klareskog, L. Alfredsson, S. Rantapää-Dahlqvist, E. Berglin, P. Stolt, and L. Padyukov, “What precedes development of rheumatoid arthritis?” Annals of the Rheumatic Diseases, vol. 63, supplement 2, pp. ii28–ii31, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Morita, M. Yamamura, M. Kawashima et al., “Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium,” Rheumatology International, vol. 20, no. 2, pp. 49–54, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Zurawski and J. E. de Vries, “Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells,” Immunology Today, vol. 15, no. 1, pp. 19–26, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Punnonen, G. Aversa, B. G. Cocks et al., “Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 8, pp. 3730–3734, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. C. S. Haas, M. A. Amin, J. H. Ruth et al., “In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 56, no. 8, pp. 2535–2548, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Lubberts, L. A. B. Joosten, M. Chabaud et al., “IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion,” The Journal of Clinical Investigation, vol. 105, no. 12, pp. 1697–1710, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. M.-C. Boissier, “Cell and cytokine imbalances in rheumatoid synovitis,” Joint Bone Spine, vol. 78, no. 3, pp. 230–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Spadaro, T. Rinaldi, V. Riccieri, E. Taccari, and G. Valesini, “Interleukin-13 in autoimmune rheumatic diseases: relationship with the autoantibody profile,” Clinical and Experimental Rheumatology, vol. 20, no. 2, pp. 213–216, 2002. View at Google Scholar · View at Scopus
  29. L. Barra, K. Summers, D. Bell, and E. Cairns, “Serum cytokine profile of unaffected first-degree relatives of patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 41, no. 2, pp. 280–285, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Woods, G. K. Haines, M. R. Shah, G. Rayan, and A. E. Koch, “Low-level production of interleukin-13 in synovial fluid and tissue from patients with arthritis,” Clinical Immunology and Immunopathology, vol. 85, no. 2, pp. 210–220, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. A. N. J. McKenzie, J. A. Culpepper, R. De Waal Malefyt et al., “Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 8, pp. 3735–3739, 1993. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Roubenoff, R. A. Roubenoff, J. G. Cannon et al., “Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation,” The Journal of Clinical Investigation, vol. 93, no. 6, pp. 2379–2386, 1994. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Tokayer, S. E. Carsons, B. Chokshi, and F. Santiago-Schwarz, “High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity,” The Journal of Rheumatology, vol. 29, no. 3, pp. 454–461, 2002. View at Google Scholar · View at Scopus
  34. P. Isomäki, R. Luukkainen, P. Toivanen, and J. Punnonen, “The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 39, no. 10, pp. 1693–1702, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Raza, F. Falciani, S. J. Curnow et al., “Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin,” Arthritis Research & Therapy, vol. 7, no. 4, pp. 784–795, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. J. E. De Vries and G. Zurawski, “Immunoregulatory properties of IL-13: its potential role in atopic disease,” International Archives of Allergy and Immunology, vol. 106, no. 3, pp. 175–179, 1995. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Arroyo-Villa, M.-B. Bautista-Caro, A. Balsa et al., “Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivity,” PLoS ONE, vol. 7, no. 8, Article ID e42189, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Avouac, L. Gossec, and M. Dougados, “Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review,” Annals of the Rheumatic Diseases, vol. 65, no. 7, pp. 845–851, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Sarkar and D. A. Fox, “Targeting IL-17 and Th17 cells in rheumatoid arthritis,” Rheumatic Disease Clinics of North America, vol. 36, no. 2, pp. 345–366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Pöllinger, T. Junt, B. Metzler et al., “Th17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans,” Journal of Immunology, vol. 186, no. 4, pp. 2602–2612, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Kokkonen, I. Söderström, J. Rocklöv, G. Hallmans, K. Lejon, and S. R. Dahlqvist, “Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 62, no. 2, pp. 383–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Lubberts, “Th17 cytokines and arthritis,” Seminars in Immunopathology, vol. 32, no. 1, pp. 43–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. E. M. Moran, R. Mullan, J. McCormick et al., “Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies,” Arthritis Research & Therapy, vol. 11, no. 4, article R113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Shen, J. C. Goodall, and J. S. Hill Gaston, “Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis,” Arthritis and Rheumatism, vol. 60, no. 6, pp. 1647–1656, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Leipe, M. Grunke, C. Dechant et al., “Role of Th17 cells in human autoimmune arthritis,” Arthritis & Rheumatism, vol. 62, no. 10, pp. 2876–2885, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Fossiez, O. Djossou, P. Chomarat et al., “T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines,” Journal of Experimental Medicine, vol. 183, no. 6, pp. 2593–2603, 1996. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Chabaud, F. Fossiez, J.-L. Taupin, and P. Miossec, “Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines,” The Journal of Immunology, vol. 161, no. 1, pp. 409–414, 1998. View at Google Scholar · View at Scopus
  48. M. V. Volin and S. Shahrara, “Role of TH-17 cells in rheumatic and other autoimmune diseases,” Rheumatology (Sunnyvale), vol. 1, no. 104, article 2169, 2011. View at Publisher · View at Google Scholar
  49. M. C. Genovese, F. Van Den Bosch, S. A. Roberson et al., “LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, Proof-of-Concept Study,” Arthritis and Rheumatism, vol. 62, no. 4, pp. 929–939, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Cai, J. P. Yin, M. A. Starovasnik et al., “Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo,” Cytokine, vol. 16, no. 1, pp. 10–21, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. V. Pavlovic, A. Dimic, S. Milenkovic, and D. Krtinic, “Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis,” Journal of Research in Medical Sciences, vol. 19, no. 1, pp. 18–22, 2014. View at Google Scholar · View at Scopus
  52. Z. Reyes-Castillo, C. A. Palafox-Sánchez, I. Parra-Rojas et al., “Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features,” Clinical and Experimental Immunology, vol. 182, no. 2, pp. 119–131, 2015. View at Publisher · View at Google Scholar · View at Scopus